Filing Details
- Accession Number:
- 0001144204-12-007402
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-02-10 21:34:29
- Reporting Period:
- 2012-02-08
- Filing Date:
- 2012-02-10
- Accepted Time:
- 2012-02-10 21:34:29
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1087939 | Julian Baker | 667 Madison Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No | |
1087940 | Felix Baker | 667 Madison Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No | |
1307729 | Baker Brothers Life Sciences Capital (Gp), Llc | 667 Madison Avenue, 21St Floor New York NY US 10065 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-02-08 | 6,093 | $26.17 | 6,907,796 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-08 | 135,681 | $26.18 | 7,043,477 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-08 | 60,315 | $26.26 | 7,103,792 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-09 | 2,441 | $26.27 | 7,106,233 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-09 | 49,670 | $26.33 | 7,155,903 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-09 | 3,883 | $26.24 | 7,159,786 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-10 | 112,735 | $26.60 | 7,272,521 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-10 | 18,628 | $26.62 | 7,291,149 | No | 4 | P | Indirect | Through Partnership |
Common Stock | Acquisiton | 2012-02-10 | 28,469 | $26.52 | 7,319,618 | No | 4 | P | Indirect | Through Partnership |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
No | 4 | P | Indirect | Through Partnership |
Footnotes
- In addition to Baker Brothers Life Sciences Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker each of whom has the same business address as Baker Brothers Life Sciences Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Julian C. Baker is a director of the Issuer. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (Continued in footnote 2).
- However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
- Represents securities owned directly by Baker Brothers Life Sciences, L.P., the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP),LLC. Julian C. Baker and Felix J. Baker are controlling members of Baker Brothers Life Sciences Capital (GP), LLC.